Effects of Bevacizumab on Autocrine VEGF Stimulation in Bladder Cancer Cell LinesVideira P.A.a · Piteira A.R.a · Cabral M.G.a · Martins C.a · Correia M.a · Severino P.a · Gouveia H.a · Carrascal M.a · Almeida J.F.a · Trindade H.a · Santos L.L.b
aCEDOC, Departamento de Imunologia, Faculdade de Ciências Médicas, FCM, Universidade Nova de Lisboa, Lisboa, and bDepartamento de Oncologia Cirúrgica, Instituto Português de Oncologia do Porto e Universidade Fernando Pessoa, Porto, Portugal
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Introduction: A functional vascular endothelial growth factor A (VEGF-A) autocrine loop is crucial for bladder cancer cell survival. We reasoned that treatment with the anti-VEGF antibody bevacizumab may result either in cell growth prevention or in the cell adaptation to compensate VEGF deprivation. Methods: The cytotoxicity of different levels of bevacizumab and its effect on the gene expression was analyzed in human bladder cancer cell lines. Results: Inhibition of bladder cancer cell proliferation was observed at >2.5 mg/ml of bevacizumab. Non-muscle-invasive bladder cancer cells expressed high concentrations of VEGF-A, and were less susceptible to bevacizumab inhibition. At 0.5 mg/ml (FDA approved concentration) of bevacizumab, cells increase their expression of VEGF-A, VEGF-A receptors and related growth factors. Conclusions: Bevacizumab cytotoxicity is only observed at high concentration, and it is inversely correlated with the basal VEGF-A expression of the bladder cancer cells. This is the first report showing that, at clinical bevacizumab concentrations, cancer cells compensate the VEGF-A blockade, by improving the expression of VEGF-A and related genes, highlighting the need to follow the patient’s adaptation response to bevacizumab treatment.
© 2011 S. Karger AG, Basel
- Folkman J, Shing Y: Angiogenesis. J Biol Chem 1992;267:10931–10934.
- Ferrara N, Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851–858.
- Ferrara N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10–14.
Wey JS, Stoeltzing O, Ellis LM: Vascular endothelial growth factor receptors: expression and function in solid tumors. Clin Adv Hematol Oncol 2004;2:37–45.
- Gee MF, Tsuchida R, Eichler-Jonsson C, Das B, Baruchel S, Malkin D: Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid. Oncogene 2005;24:8025–8037.
- Crew JP, O’Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D, Harris AL: Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997;57:5281–5285.
- Black PC, Dinney CP: Bladder cancer angiogenesis and metastasis – translation from murine model to clinical trial. Cancer Metastasis Rev 2007;26:623–634.
- Kunze D, Wuttig D, Kausch I, Blietz C, Blumhoff L, Burmeister Y, Kraemer K, Fuessel S, Toma M, Schwenzer B, Meye A, Grimm MO, Hakenberg OW, Jocham D, Wirth MP: Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int J Oncol 2008;32:1049–1056.
- Nakanishi R, Oka N, Nakatsuji H, Koizumi T, Sakaki M, Takahashi M, Fukumori T, Kanayama HO: Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer. Urol Int 2009;83:98–106.
- Goddard JC, Sutton CD, Furness PN, O’Byrne KJ, Kockelbergh RC: Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clin Cancer Res 2003;9:2583–2586.
- Canoglu A, Gogus C, Beduk Y, Orhan D, Tulunay O, Baltaci S: Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis. Int Urol Nephrol 2004;36:401–405.
- Elfiky AA, Rosenberg JE: Targeting angiogenesis in bladder cancer. Curr Oncol Rep 2009;11:244–249.
- Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843–850.
- Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.
- Scott LJ: Bevacizumab: in first-line treatment of metastatic breast cancer. Drugs 2007;67:1793–1799.
- Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427–434.
- Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.
- Videira PA, Correia M, Malagolini N, Crespo HJ, Ligeiro D, Calais FM, Trindade H, Dall’Olio F: ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines. BMC Cancer 2009;9:357.
Videira PA, Ligeiro D, Correia M, Trindade H: Gene expression analysis in superficial bladder cancer: comparison of two suitable endogenous reference genes. Curr Urol 2007;1:145–150.
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(–delta delta C(T)) method. Methods 2001;25:402–408.
- Fogh J, Fogh JM, Orfeo T: One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 1977;59:221–226.
- O’Toole C, Perlmann P, Unsgaard B, Moberger G, Edsmyr F: Cellular immunity to human urinary bladder carcinoma. I. Correlation to clinical stage and radiotherapy. Int J Cancer 1972;10:77–91.
- Rasheed S, Gardner MB, Rongey RW, Nelson-Rees WA, Arnstein P: Human bladder carcinoma: characterization of two new tumor cell lines and search for tumor viruses. J Natl Cancer Inst 1977;58:881–890.
- Marzioni D, Lorenzi T, Mazzucchelli R, Capparuccia L, Morroni M, Fiorini R, Bracalenti C, Catalano A, David G, Castellucci M, Muzzonigro G, Montironi R: Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. Int J Immunopathol Pharmacol 2009;22:627–638.
- Wu W, Shu X, Hovsepyan H, Mosteller RD, Broek D: VEGF receptor expression and signaling in human bladder tumors. Oncogene 2003;22:3361–3370.
- O’Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL: Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res 1995;55:510–513.
- Wang Y, An R, Dong X, Pan S, Duan G, Sun X: Protein kinase C is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in human bladder cancer cells. Urol Int 2009;82:214–221.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.